Carolyn Laurencot
FDA (US Food and Drug Administration)
Associate Director for Regulatory Science and Review, Division of Cellular & G
Carrie Laurençot joined the Division of Cellular and Gene Therapies (DCGT), in the Office of Tissues and Advanced Therapies (OTAT) in the FDA’s Center for Biologics Evaluation and Research (CBER) in 2019 and serves as the Associate Director for Regulatory Science and Review. In this role, she advises DCGT leadership on regulatory and scientific issues, provides input on development and evaluation of new policies, and on scientific and regulatory programs pertinent to the Agency.
Dr. Laurençot obtained a Ph.D. in Pharmacology from The George Washington University and has over 25 years of experience in medical product development in the pharmaceutical industry and the U.S. federal government where she provided regulatory support and advice for numerous gene and cell therapy development projects, as well as projects for other biologics and drugs.
Dr. Laurençot obtained a Ph.D. in Pharmacology from The George Washington University and has over 25 years of experience in medical product development in the pharmaceutical industry and the U.S. federal government where she provided regulatory support and advice for numerous gene and cell therapy development projects, as well as projects for other biologics and drugs.